Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) CEO Interview with James F. Oliviero discussing clinical progress in company’s pipeline of cancer drugs, addressing multi-billion dollar markets. The company’s lead drug is in late stage clinical trials, with potential commercialization within next 3 years.
Investor Presentation
Checkpoint Presentation_CKPT_January 2019
VANCOUVER, Washington, Aug. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]
VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]
ISFIYA, Israel, May 04, 2018 — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW, CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
